Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.

Ralf GoldDouglas Lorne ArnoldAmit Bar-OrRobert J Fox Ludwig KapposOksana MokliatchoukXiaotong JiangJennifer LyonsShivani KapadiaCatherine Miller

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

Sustained DMF safety/efficacy was observed in patients followed up to 13 years, supporting DMF's positive benefit/risk profile for long-term RRMS treatment.

Keyphrases

multiple sclerosis
end stage renal disease
newly diagnosed
ejection fraction
white matter
chronic kidney disease
prognostic factors
peritoneal dialysis
disease activity
rheumatoid arthritis
patient reported outcomes
combination therapy
systemic lupus erythematosus